Terms: = Kidney tumors AND RAF1, Raf-1, 5894, P04049, ENSG00000132155, c-Raf, CRAF AND Treatment
14 results:
1. Mesenchymal neoplasms with NTRK and other kinase gene alterations.
Davis JL; Al-Ibraheemi A; Rudzinski ER; Surrey LF
Histopathology; 2022 Jan; 80(1):4-18. PubMed ID: 34958503
[TBL] [Abstract] [Full Text] [Related]
2. Transcriptional and post-translational modifications of B-Raf in quinol-thioether induced tuberous sclerosis renal cell carcinoma.
Cohen JD; Labenski M; Mastrandrea NJ; Canatsey RD; Monks TJ; Lau SS
Mol Carcinog; 2016 Aug; 55(8):1243-50. PubMed ID: 26333016
[TBL] [Abstract] [Full Text] [Related]
3. Indole-3-carbinol inhibits cell proliferation and induces apoptosis in Hep-2 laryngeal cancer cells.
Wang YQ; Chen C; Chen Z; Xu Y; Wang Y; Xiao BK; Chen SM; Tao ZZ
Oncol Rep; 2013 Jul; 30(1):227-33. PubMed ID: 23604413
[TBL] [Abstract] [Full Text] [Related]
4. Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells.
Zhu Y; Xu L; Zhang J; Hu X; Liu Y; Yin H; Lv T; Zhang H; Liu L; An H; Liu H; Xu J; Lin Z
Cancer Sci; 2013 Aug; 104(8):1052-61. PubMed ID: 23578198
[TBL] [Abstract] [Full Text] [Related]
5. Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth.
Dudgeon C; Peng R; Wang P; Sebastiani A; Yu J; Zhang L
Oncogene; 2012 Nov; 31(46):4848-58. PubMed ID: 22286758
[TBL] [Abstract] [Full Text] [Related]
6. ERK crosstalks with 4EBP1 to activate cyclin D1 translation during quinol-thioether-induced tuberous sclerosis renal cell carcinoma.
Cohen JD; Gard JM; Nagle RB; Dietrich JD; Monks TJ; Lau SS
Toxicol Sci; 2011 Nov; 124(1):75-87. PubMed ID: 21813464
[TBL] [Abstract] [Full Text] [Related]
7. Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
Jain L; Woo S; Gardner ER; Dahut WL; Kohn EC; Kummar S; Mould DR; Giaccone G; Yarchoan R; Venitz J; Figg WD
Br J Clin Pharmacol; 2011 Aug; 72(2):294-305. PubMed ID: 21392074
[TBL] [Abstract] [Full Text] [Related]
8. [Sorafenib(Nexavar)].
Miyanaga N; Akaza H
Gan To Kagaku Ryoho; 2009 Jun; 36(6):1029-33. PubMed ID: 19542731
[TBL] [Abstract] [Full Text] [Related]
9. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
Hiles JJ; Kolesar JM
Am J Health Syst Pharm; 2008 Jan; 65(2):123-31. PubMed ID: 18192256
[TBL] [Abstract] [Full Text] [Related]
10. Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib.
Bracarda S; Caserta C; Sordini L; Rossi M; Hamzay A; Crinò L
Ann Oncol; 2007 Jun; 18 Suppl 6():vi22-5. PubMed ID: 17591826
[TBL] [Abstract] [Full Text] [Related]
11. [Angiogenesis and renal cell carcinoma].
Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
[TBL] [Abstract] [Full Text] [Related]
12. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
Sosman JA; Puzanov I; Atkins MB
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
[TBL] [Abstract] [Full Text] [Related]
13. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Strumberg D
Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
[TBL] [Abstract] [Full Text] [Related]
14. Kinase inhibition with BAY 43-9006 in renal cell carcinoma.
Ahmad T; Eisen T
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6388S-92S. PubMed ID: 15448036
[TBL] [Abstract] [Full Text] [Related]
